NAT2 and tuberculosis: However, it is worth mentioning the limitations of this study as well, such as the lack of complete clinical data from some patients, detailed information about therapy with other drugs (possible substrates of NAT2), and the lack of analysis of additional variants in other genes, also involved in the metabolism of anti-TB drugs, that could change the risk association of NAT2 variants for the development of anti-TB DIH.